These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16938666)

  • 1. Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
    Chu PG; Loera S; Huang Q; Weiss LM
    Am J Clin Pathol; 2006 Oct; 126(4):534-44. PubMed ID: 16938666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases.
    Oliveira JL; Grogg KL; Macon WR; Dogan A; Feldman AL
    Am J Surg Pathol; 2012 Sep; 36(9):1364-70. PubMed ID: 22895269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.
    Blakolmer K; Vesely M; Kummer JA; Jurecka W; Mannhalter C; Chott A
    Mod Pathol; 2000 Jul; 13(7):766-72. PubMed ID: 10912936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion.
    Hoeller S; Tzankov A; Feichter G; Obermann E; Dirnhofer S
    Cytopathology; 2009 Aug; 20(4):273-4. PubMed ID: 19207312
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.
    Kanavaros P; Gaulard P; Charlotte F; Martin N; Ducos C; Lebezu M; Mason DY
    Am J Pathol; 1995 Mar; 146(3):735-41. PubMed ID: 7887454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.
    Yao X; Teruya-Feldstein J; Raffeld M; Sorbara L; Jaffe ES
    Mod Pathol; 2001 Feb; 14(2):105-10. PubMed ID: 11235901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
    Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
    Marmey B; Boix C; Barbaroux JB; Dieu-Nosjean MC; Diebold J; Audouin J; Fridman WH; Mueller CG; Molina TJ
    Hum Pathol; 2006 Jan; 37(1):68-77. PubMed ID: 16360418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia.
    Huh YO; Keating MJ; Saffer HL; Jilani I; Lerner S; Albitar M
    Am J Clin Pathol; 2001 Sep; 116(3):437-43. PubMed ID: 11554173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orbital plasmablastic lymphoma--comparison of a newly reported entity with diffuse large B-cell lymphoma of the orbit.
    Morley AM; Verity DH; Meligonis G; Rose GE
    Orbit; 2009; 28(6):425-9. PubMed ID: 19929677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker.
    Nasr MR; Rosenthal N; Syrbu S
    Am J Clin Pathol; 2010 Jan; 133(1):41-8. PubMed ID: 20023257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
    Schniederjan SD; Li S; Saxe DF; Lechowicz MJ; Lee KL; Terry PD; Mann KP
    Am J Clin Pathol; 2010 May; 133(5):718-26. PubMed ID: 20395518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
    Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
    Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.
    Zettl A; Rüdiger T; Marx A; Müller-Hermelink HK; Ott G
    Histopathology; 2005 Feb; 46(2):217-28. PubMed ID: 15693895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
    Hoeller S; Zihler D; Zlobec I; Obermann EC; Pileri SA; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jan; 56(2):217-28. PubMed ID: 20102401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.